Catalyst

Slingshot members are tracking this event:

PDUFA date for TAF NDA in HBeAg and HBeAG+ chronic HBV infection set for Nov 11 2016

Source Link:
http://www.gilead.com/news/press-releases/2016/4/gilead-announces-full-48week-results-from-two-phase-3-studies-evaluating-tenofovir-alafenamide-taf-for-patients-with-chronic-hepatitis-b-infection

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GILD Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Nov 10, 2016
Occurred Source:
http://www.gilead.com/news/press-releases/2016/11/us-food-and-drug-administration-approves-gileads-vemlidy-tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Pdufa, Taf, Nda Filing, Hbeag, Chronic Hbv
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.